Amylyx Pharmaceuticals (AMLX) Return on Capital Employed (2022 - 2026)

Amylyx Pharmaceuticals' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 53.6% for Q1 2026.

• On a quarterly basis, Return on Capital Employed rose 6849.0% year-over-year to 53.6% in Q1 2026; TTM through Mar 2026 was 53.6%, a 6849.0% increase from a year earlier, with the FY2025 full-year figure at 63.75%, up 3246.0% from the prior year.
• Return on Capital Employed fell to 53.6% in Q1 2026 per AMLX's latest filing, from 47.17% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 9.46% in Q4 2023 and bottomed at 162.43% in Q4 2024.
• The 5-year median for Return on Capital Employed is 62.22% (2025), against an average of 67.12%.
• Across the five-year window, Return on Capital Employed plunged 17189 bps in 2024 and surged 11526 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 83.95% in 2022, then soared by 111 bps to 9.46% in 2023, then plunged by 1816 bps to 162.43% in 2024, then jumped by 71 bps to 47.17% in 2025, then dropped by 14 bps to 53.6% in 2026.
• Per Business Quant, the three latest AMLX Return on Capital Employed figures stand at 53.6% (Q1 2026), 47.17% (Q4 2025), and 62.22% (Q3 2025).